A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

PHASE3CompletedINTERVENTIONAL
Enrollment

632

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Chronic Kidney DiseaseDialysisHyperphosphatemia
Interventions
DRUG

MCI-196

3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose

DRUG

Another Phosphate binder (Sevelamer)

Current approved dosing recommendations for 12 weeks

Trial Locations (115)

Unknown

Graz

Frýdek-Místek

Hradec Králové

Ostrava

Prague

Tábor

Ústí nad Labem

Bordeaux

Montpelier

Paris

Aschaffenburg

Coesfeld

Darmstadt

Dortmund

Düsseldorf

Hamburg

Homberg (Efze)

Langen

Mannheim-Kafertal

Ajka

Baja

Budapest

Esztergom

Győr

Hatvan

Kisvárda

Veszprém

Ancona

Cernusco sul Naviglio

Como

Cremona

Lecco

Livorno

Milan

Modena

Ostia Roma

Pavia

Perugia

Rome

Alor Star

Klang

Kota Kinabalu

Kuala Terengganu

Kuching

Malacca

Selangor Darul Ehsan

Seremban

Taiping

Skopje

Ciechanów

Częstochowa

Gdansk

Lodz

Lublin

Oświęcim

Pabianice

Poznan

Rybnik

Sokołów Podlaski

Starogard Gdański

Warsaw

Wejherowo

Wroclaw

Zgierz

Zielona Góra

Arkhangelsk

Chita

Irkutsk

Ivanovo

Kaluga

Karbysheva str.Volzskiy

Kemerovo

Khabarovsk

Krasnodar

Krasnoyarsk

Moscow

Mytishchi

Nizhny Novgorod

Novokuznetsk

Novorossiysk

Novosibirsk

Omsk

Petrozavodsk

Rostov-on-Don

Rozhkova

Saint Petersburg

Smolensk

Tomsk

Vladivostok

Yaroslavl

Yekaterinburg

Belgrade

Kragujevac

Niš

Novi Sad

Cape Town

Durban

Gauteng

Johannesburg

Port Elizabeth

Barcelona

Oviedo

Seville

Chernivtsy

Dnipro

Ivano-Frankivsk

Kharkiv

Kiev

Mykolayiv

Ternopil

Uzhhorod

Zaporizhya

Zhytomyr

Glasgow

Stevenage

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY